NCT05727319Completed
Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC)
Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC): a Single Centre Feasibility Study
Source: ClinicalTrials.gov · Last updated 7 Feb 2025
Brief summary (registry, in English)
The goal of this observational study is to determine the feasibility of acquiring serial MRI images for longitudinal analysis in pancreatic ductal adenocarcinoma (PDAC) patients. The main question it aims to answer: Is it feasible to acquire baseline and repeat MR images in Radiotherapy treatment position?
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 13 (actual)
- First submitted
- 11 Jan 2023
- Start date
- 17 Nov 2022
- Primary completion date
- 17 May 2024
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Diseases
- Pancreatic cancer
- NCT number
- NCT05727319
What you commit to
- Study type: Observational
- Participants enrolled: 13
- From 17 Nov 2022 to the primary completion date, 17 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major surgery within 28 days prior to trial entry
- MRI unsafe implants, ferrous metal in the body, insufficient information on previous surgeries, MRI conditional implants where the conditions cannot be met (e.g. pacemakers).
Other illness
- Distant metastatic disease
- Other severe or uncontrolled systemic disease or evidence of any other significant disorder or lab finding that makes it undesirable for the patient to participate in the study, as determined by the treating physician.
- History of physical or psychiatric disorder that would prevent informed consent and compliance with protocol
Other
- Any contraindication to MR
Who the study is looking for
- Histologically confirmed localised PDAC -as determined by the West of Scotland Hepato-Pancreatobiliary (HPB) MDT
- Scheduled to undergo RT +/- chemotherapy
- 18 years of age or older
- Measurable disease on imaging
- Able to give written informed consent
- Patients willing and able to comply with the protocol for the duration of the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beatson West of Scotland Cancer Centre Coordinator of this site? Confirm its status | Glasgow | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.